Kimberly K. Leslie, MD

Portrait

Chair and DEO, Obstetrics and Gynecology
Professor of Obstetrics and Gynecology  - Maternal/Fetal Medicine

Contact Information

Primary Office: 31140-A PFP
Iowa City, IA 52242

Email: kimberly-leslie@uiowa.edu

Education

BS, Psychology, Baylor University, Waco, Texas
BS, Biology and Biochemistry, Texas Christian University, Fort Worth, Texas
MD, Medicine, Southwestern Medical School, University of Texas, Dallas, Texas

Residency, Obstetrics and Gynecology, Parkland Memorial Hospital, Dallas, Texas
Residency, Obstetrics and Gynecology, Georgetown University Affilated Hospitals, Washington, D.C.
Fellowship, Maternal-Fetal Medicine, Georgetown University, Washington, D.C.

Education/Training Program Affiliations

Biosciences Graduate Program
Interdisciplinary Graduate Program in Molecular and Cellular Biology
Interdisciplinary Graduate Program in Translational Biomedicine
Medical Scientist Training Program

Research Summary

Dr. Leslie has received consistent research funding since 1989 and is the recipient of more than 22 peer-reviewed grants. Among these are the Reproductive Scientist Development Program (RSDP) and the American Obstetrical and Gynecologic Foundation/Burroughs Wellcome Fellowship. These mentored grants, received while undertaking post-doctoral research training in the laboratories of Drs. Janice Chou, intramural NICHD, and Kathryn Horwitz, the University of Colorado, were followed by the award of an R03, R21, and R29 from NIH. Her latest work is supported by the NCI via an R01 entitled, “Targeted Therapy for Endometrial Cancer” in addition to numerous foundation and Cancer Center awards. Leslie has served on numerous NIH study sections and editorial boards of peer-reviewed journals. Dr. Leslie now trains post-doctoral fellows, residents, and students in her own laboratory that investigates the molecular biology of hormone action and hormone receptors in reproductive tissues. Her greatest research contribution has focused on the response to steroid stimulation and the phenotypic and genomic mechanisms in endometrial cancer. New areas of focus include sub-cellular localization of progesterone receptors, proteomics as a tool for cancer screening, and progesterone receptor cross-talk with the growth factors and other signaling molecules. Dr. Leslie’s laboratory has also made observations pertaining to the molecular pathways affected in preeclampsia, and these findings were the subject of plenary talks at the Society for Maternal-Fetal Medicine meetings in 2008 and 2009. Dr. Leslie continues to be active in the clinical care of women with pregnancy complications and serves as an examiner for the American Board of Obstetrics and Gynecology.

All Publications

Zaino R, Brady W, Todd W, Leslie K, Fischer E, Horowitz N, Mannel R, Walker J, Ivanovic M, Duska L.  Histologic Effects of Medroxyprogesterone Acetate on Endometrioid Endometrial Adenocarcinoma: a Gynecologic Oncology Group study. [Epub ahead of print].  Int J Gynecol Pathol.  2014 October 1. 
[PubMed]

Dunkelberg J, Berkley E, Thiel K, Leslie K.  Hepatitis B and C in pregnancy: a review and recommendations for care [Epub ahead of print].  J Perinatol.  2014 September 18. 
[PubMed]

Yang S, Leslie K, Jia Y, Liu X, Winters C, Wang X, Zhang Y, Devor E, Hovey A, Reyes H, Xiao X, Xu Y, Dai D, Meng X, Thiel K, Domann F.  Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer [Epub ahead of print].  Oncotarget.  2014 September 2. 
[PubMed]

Santillan M, Leslie K, Hamilton W, Boese B, Ahuja M, Hunter S, Santillan D.  Collection of a Lifetime: A Practical Approach to Developing a Longitudinal Collection of Women’s Healthcare Biological Samples.  European J Obstet Gynecol Repro Biol. .  2014 August. 179:94-99.

Powell M, Sill M, Goodfellow P, Benbrook D, Lankes H, Leslie K, Jeske Y, Mannel R, Spillman M, Lee P, Hoffman J, McMeekin D, Pollock P.  A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study..  Gynelcol Oncol [Epub ahead of print].  2014 July 11. 
[PubMed]

Santillan M, Santillan D, Scroggins S, Min J, Sangren J, Pearson N, Leslie K, Hunter S, Zamba G, Gibson-Gorley K, Grobe J.  Vasopressin in Preeclampsia: A Novel Very Early Human Pregnancy Biomarker and Clinically Relevant Mouse Model.  Hypertenson.  2014 July 7. 
[PubMed]

Kresowik J, Devor E, Van Voorhis B, Leslie K.  MicroRNA-31 Is Significantly Elevated in Both Human Endometrium and Serum During the Window of Implantation: A Potential Biomarker for Optimum Receptivity. [Epub ahead of print].  Biol Reprod.  2014 May 22. 
[PubMed]

Carlson M, Thiel K, Leslie K.  Past, present, and future of hormonal therapy in recurrent endometrial cancer. [eCollection 2014].  Int J Womens Health.  2014 May 2. 2(6):429-435.

Devor E, Schickling B, Leslie K.  microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families..  Biomed Rep. .  2014 May. 2(3):384-387.

Devor E, Reyes H, Santillan D, Santillan M, Onukwugha C, Goodheart M, Leslie K.  Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions..  Obstet Gynecol Int..  2014 March 17. 2014.

Fleming G, Filiaci V, Marzullo B, Zaino R, Davidson S, Pearl M, Makker V, Burke J, Zweizig S, Van Le L, Hanjani P, Downey G, Walker J, Reyes H, Leslie K.  Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.  Gynecol Oncol.  2014 March. 132(3):585-92.
[PubMed]

Reyes H, Thiel K, Carlson M, Meng X, Yang S, Stephan J, Leslie K.  Comprehensive Profiling of EGFR/HER Receptors for Personalized Treatment of Gynecologic Cancers..  Mol Diagn Ther.  2014 January 9. 
[PubMed]

Leslie K.  Gynecologic Oncology Group Study 229C: Personal Reflection.  Proceedings in Obstetrics and Gynecology.  2013 November 4. 3(4):Article 2 [2p.].
[Link]

Brachova P, Thiel K, Leslie K.  The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer..  Int J Mol Sci.  2013 September 23. 14(9):19257-75.
[PubMed]

Leslie K, Thiel K, Reyes H, Yang S, Zhang Y, Carlson M, Kumar N, Dai D.  The estrogen receptor joins other cancer biomarkers as a predictor of outcome..  Obstetrics and Gynecology International.  2013 September 10. 2013:5 pages.

Yang S, Leslie K, Meng X.  MTDH and FOXM1, Two Master Regulators in Gynecologic Cancer.  Med J Obstet Gynecol.  2013 September 2. 1(1):1009.

Leslie K, Niebyl J.  A statement on abortion by 100 professors of obstetrics: 40 years later .  American Journal of Obstetrics and Gynecology.  2013 September. 209(3):193-199.

Yang S, Xiao X, Jia Y, Liu X, Devor E, Meng X, Thiel K, Leslie K.  Epigenetic Modification Restores Functional PR Expression in Endometrial Cancer Cells.  Curr Pharm Des.  2013 July 19. 

Santillan M, Devor E, Leslie K, Hunter S, Santillan D.  A microRNA expression profile of normal placental development.  Poster Presentation at the Society for Gynecologic Investigation 60th Annual Meeting, Orlando, FL.  2013 March. 

Kowalski J, Netz R, Sinkey C, Santillan D, Fleener D, Hamilton W, Boese B, Hunter S, Leslie K, Hayes W, Santillan M.  Changes in flow mediated vasodilation predicts development of gestational diabetes.  Poster Presentation at the Society for Gynecologic Investigation 60th Annual Meeting, Orlando, FL.  2013 March. 

Meng X, Laidler L, Kosmacek E, Yang S, Xiong Z, Zhu D, Wang X, Dai D, Zhang Y, Wang X, Brachova P, Albitar L, Liu D, Ianzini F, Mackey M, Leslie K.  Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53..  Gynecologic oncology.  2013 March. 128(3):461-9.
[PubMed]

Santillan D, Ahuja M, Wang Y, Knosp B, Leslie K, Junter S, Santillan M.  Novel web portal to view integrated biorepository and EMR data.  Poster Presentation at the Society for Gynecologic Investigation 60th Annual Meeting, Orlando, FL.  2013 March. 

Talcott K, Christensen A, Tyler E, Hamilton W, Boese B, Santillan D, Hunter S, Leslie K, Santillan M.  The effect of obesity on C-reactive protein levels and poor pregnancy outcomes.  Poster Presentation at the Society for Gynecologic Investigation 60th Annual Meeting, Orlando, FL.  2013 March. 

Leslie K, Sill M, Fischer E, Darcy K, Mannel R, Tewari K, Hanjani P, Wilken J, Baron A, Godwin A, Schilder R, Singh M, Maihle N.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study..  Gynecologic oncology.  2013 February. 
[PubMed]

Meng X, Thiel K, Leslie K.  Drug Resistance Mediated by AEG-1/MDTH/LYRIC (Chapter 5).  Advances in Cancer Research.  2013. 120:135-157.

Meng X, Thiel K, Leslie K.  Drug Resistance Mediated by AEG-1/MTDH/LYRIC..  Adv Cancer Res.  2013. 120(135-57).
[PubMed]

Yang S, Jia Y, Liu X, Xiao X, Zhang Y, Devor E, Meng X, Leslie K.  Enhancing hormone therapy in endometrial cancer by differentially targeting epigenetic repression of progesterone receptor expression.  American Association for Cancer Research Annual Meeting, Washington, D.C..  2013. 

Thiel K, Meng X, Reyes H, Zhang Y, Leslie K.  p53 status directs choice of molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial cancer.  2013 American Association for Cancer Research Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities, Bellevue, WA .  2013. 

Meng X, Yang S, Zhu D, Wang X, Thiel K, Leslie K.  Strategies for molecularly enhanced chemotherapy in endometrial tumors with mutant p53.  2013 American Association for Cancer Research Annual Meeting, Washington, D.C.  2013. 

Yang S, Jia Y, Devor E, Meng X, Thiel K, Leslie K.  Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer.  2nd Congress on Steroid Research, Chicago, IL. * invited for oral presentation (S Yang).  2013. 

Devor E, Leslie K.  The Onco-placental Gene Placenta-specific protein 1 (PLAC1) is Highly Expressed in Endometrial Tumors and Cell Line.  Obstet Gynecol Intl.  2013. 

Leslie K, Sill M, Lankes H, Fischer E, Godwin A, Gray H, Schilder R, Walker J, Tewari K, Hanjani P, Abulafia O, Rose P.  Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer..  Gynecologic oncology.  2012 November. 127(2):345-50.
[PubMed]

Kresowik J, Devor E, Van Voorhis B, Leslie K.  MicroRNA-31 is upregulated in the serum during the windown of implantation.  American Society of Reproductive Medicine Meeting, San Diego, CA.  2012 October. 

Carlson M, Thiel K, Yang S, Leslie K.  Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer..  Discovery medicine.  2012 September. 14(76):215-22.
[PubMed]

Leslie K, Thiel K, Goodheart M, De Geest K, Jia Y, Yang S.  Endometrial cancer.  Obstetrics and gynecology clinics of North America.  2012 June. 39(2):255-68.
[PubMed]

Leslie K, Thiel K, Goodheart M, De Geest K, Jia Y, Yang S.  Endometrial Cancer.  Obstetrics and Gynecology Clinics of North America.  2012 June. 39(2):255-68.

Yang S, Xiao X, Zhang Y, Meng X, Leslie K.  Epigenetic modulation restores expression of functional progesterone receptor in endometrial cancer cells.  Poster Session, Abstract #4711, AACR 103rd Annual Meeting, Chicago, IL.  2012 April. 

Devor E, DE Mik J, Ramachandran S, Goodheart M, Leslie K.  Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma..  Experimental and therapeutic medicine.  2012 April. 3(4):677-682.
[PubMed]

Meng X, Zhu D, Wang X, Yang S, Zhang Y, Xiong Z, Leslie K.  Identification of a novel cytoplasmic role for MTDH/AEG-1 in chemoresistance as a RNA binding protein.  Poster Session, Abstract #3053, AACR 103rd Annual Meeting, Chicago, IL.  2012 April. 

Garcia A, Sill M, Lankes H, Godwin A, Mannel R, Armstrong D, Carolla R, Liepman M, Spirtos N, Fischer E, Leslie K.  A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study.  Gynecol Oncol.  2012 March. 124(3):569-74.

Garcia A, Sill M, Lankes H, Godwin A, Mannel R, Armstrong D, Carolla R, Liepman M, Spirtos N, Fischer E, Leslie K.  A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study..  Gynecologic oncology.  2012 March. 124(3):569-74.
[PubMed]

Santillan D, Leslie K, Sweezer E, Hamilton W, Empey R, Tyler E, Rushing J, Stegmann B, Hunter S, Santillan M.  Development of a Maternal Fetal Tissue Bank: An Investment in Maternal and Fetal Health Research.  Poster Presentation at Society for Gynecologic Investigation 59th Annual Meeting San Diego, CA .  2012 March. 

Santillan M, Santillan D, Hamilton W, Rayburn W, Hunter S, Leslie K.  The Th1 versus Th2 Cytokine Milieu in Control and Preeclamptic Pregnancies: A Second Trimester Predictor of Preeclampsia? .  Poster Presentation at Society for Gynecologic Investigation 59th Annual Meeting San Diego, CA .  2012 March. 

Meng X, Zhu D, Yang S, Wang X, Xiong Z, Zhang Y, Brachova P, Leslie K.  Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein..  The Journal of biological chemistry.  2012 February. 287(7):4485-91.
[PubMed]

Leslie K, Thiel K, Yang S.  Endometrial cancer: potential treatment and prevention with progestin-containing intrauterine devices..  Obstetrics and gynecology.  2012 February. 119(2 Pt 2):419-20.
[PubMed]

Gwin K, Schrader R, Peters K, Moreno A, Thiel K, Leslie K.  An exploratory study of the variables impacting preterm birth rates in New Mexico..  BMC pregnancy and childbirth.  2012. 12:53.
[PubMed]

Milhem M, Knutson T, Yang S, Zhu D, Wang X, Leslie K, Meng X.  Correlation of MTDH/AEG-1 and HOTAIR Expression with Metastasis and Response to Treatment in Sarcoma Patients..  Journal of cancer science & therapy.  2011 December. S5(4).
[PubMed]

Singh M, Darcy K, Brady W, Clubwala R, Weber Z, Rittenbach J, Akalin A, Whitney C, Zaino R, Ramirez N, Leslie K.  Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial..  Gynecologic oncology.  2011 November. 123(2):320-8.
[PubMed]

Devor E, Hovey A, Goodheart M, Ramachandran S, Leslie K.  microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs..  Oncology reports.  2011 October. 26(4):995-1002.
[PubMed]

Yang S, Thiel K, De Geest K, Leslie K.  Endometrial cancer: reviving progesterone therapy in the molecular age..  Discovery medicine.  2011 September. 12(64):205-12.
[PubMed]

Bender D, Buekers T, Leslie K.  Hormones and receptors in endometrial cancer.  Proc Obstet Gynecol.  2011 July 28. 2(1):Article 1 -25 p.

Devor E, Goodheart M, Leslie K.  Toward a microRNA signature of endometrial cancer.  Proc Obstet Gynecol.  2011 July 28. 2(1):Article 2 - p 7.

Aghajanian C, Sill M, Darcy K, Greer B, McMeekin D, Rose P, Rotmensch J, Barnes M, Hanjani P, Leslie K.  Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  2011 June. 29(16):2259-65.
[PubMed]

Yang S, Thiel K, Leslie K.  Progesterone: the ultimate endometrial tumor suppressor..  Trends in endocrinology and metabolism: TEM.  2011 April. 22(4):145-52.
[PubMed]

Davies S, Dai D, Pickett G, Thiel K, Korovkina V, Leslie K.  Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance..  Oncology reports.  2011 March. 25(3):855-62.
[PubMed]

Santillan M, Santillan D, Hamilton W, Rayburn W, Hunter S, Leslie K.  Adaptations in maternal sera of immuno-vasoactive IDO, TRAIL, and IL-4 in response to a high sFLT-1 preeclamptic environment.  Poster Session, Society for Maternal-Fetal Medicine (SMFM) Annual Meeting.  2011 February. 

Yang S, Xiao X, Meng X, Leslie K.  A mechanism for synergy with combined mTOR and PI3 kinase inhibitors..  PloS one.  2011. 6(10):e26343.
[PubMed]

Schickling B, Aykin-Burns N, Leslie K, Spitz D, Korovkina V.  An inhibitor of K+ channels modulates human endometrial tumor-initiating cells..  Cancer cell international.  2011. 11(1):25.
[PubMed]

Bolnick J, Albitar L, Laidler L, Abdullah R, Leslie K.  Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKBα/AKT and Induces Apoptosis..  Obstetrics and gynecology international.  2011. 2011:896896.
[PubMed]

Meng X, Brachova P, Yang S, Xiong Z, Zhang Y, Thiel K, Leslie K.  Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment..  PloS one.  2011. 6(6):e20920.
[PubMed]

Luo W, Wu F, Elmaoued R, Beck B, Fischer E, Meng X, Leslie K, Dai D.  Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent..  International journal of oncology.  2010 November. 37(5):1187-94.
[PubMed]

Devor E, Goodheart M, DeGeest K, Bender D, Buekers T, Leslie K.  Differential microRNA expression between normal endometrium, endometrioid adenocarcinoma, papillary serous adenocarcinoma, and carcinosarcoma.  Poster Session, AACR 101st Annual Meeting.  2010 April. 

Yang S, Pickett G, Leslie K.  Genomic and transcriptional profiling characterizes the molecular basis for response to cediranib and temsirolimus in endometrial cancer cells.  Poster presentation, AACR 101st Annual Meeting.  2010 April. 

Meng X, Laidler L, Albitar L, Holmes A, Dai D, Buekers T, Bender D, Leslie K.  The combination of paclitaxel and gefitinib inhibits endometrial cancer cells by inducing mitotic catastrophe: Proof of principle for dual therapy in endometrial cancer.  Poster presentation, AACR 101st Annual Meeting.  2010 April. 

Luo W, Wu F, Atlas S, Pickett G, Leslie K, Dai D.  Defining genetic intra-tumor heterogeneity: a chronological annotation of mutational pathways.  Proceedings in Obstetrics and Gynecology.  2010. 1(1):9.

Albitar L, Pickett G, Morgan M, Wilken J, Maihle N, Leslie K.  EGFR isoforms and gene regulation in human endometrial cancer cells..  Molecular cancer.  2010. 9:166.
[PubMed]

Davies S, Korovkina V, Meng X, Pickett G, Singh M, Dai D, Luo W, Leslie K.  Progesterone and anti-angiogenics in targeted therapy for endometrial cancer.  Poster presentation, NCI Translational Science Meeting.  2009 November. 

Sadanandan S, Hurley T, Muller C, Verschragen C, Leslie K.  Cancer in Pregnancy.  De Swiet’s Medical Complications of Pregnancy.  2009. 

LaMonica G, Ohls R, Leslie K.  Epigenetic demethylation of the sFlt-1 gene promoter results in inhibition of angiogenesis in preeclampsia.  Oral Presentation, the Society for Maternal-Fetal Medicine.  2009. 

Berkley E, Leslie K, Arora S, Qualls C, Dunkelberg J.  Chronic hepatitis C in pregnancy..  Obstetrics and gynecology.  2008 August. 112(2 Pt 1):304-10.
[PubMed]

Robinson A, Laidler L, Davies S, Leslie K.  Signaling downstream of sFlt-1 through GSK-3 underlies the pathogenesis of preeclampsia.  Oral Plenary Session presentation, Society for Maternal-Fetal Medicine.  2008. 

Leslie K.  The Genetics of Endometrial Cancer.  Invited oral presentation,the Endocrine Society.  2008. 

Leslie K, Walter S, Torkko K, Stephens J, Thompson C, Singh M.  Effect of tamoxifen on endometrial histology, hormone receptors, and cervical cytology: a prospective study with follow-up..  Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry.  2007 September. 15(3):284-93.
[PubMed]

Singh M, Zaino R, Filiaci V, Leslie K.  Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study..  Gynecologic oncology.  2007 August. 106(2):325-33.
[PubMed]

Robinson A, Watson W, Leslie K.  Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy..  The lancet oncology.  2007 August. 8(8):738-43.
[PubMed]

Albitar L, Carter M, Davies S, Leslie K.  Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer..  Gynecologic oncology.  2007 July. 106(1):94-104.
[PubMed]

Albitar L, Pickett G, Morgan M, Davies S, Leslie K.  Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells..  Gynecologic oncology.  2007 July. 106(1):52-64.
[PubMed]

Smith H, Leslie K, Singh M, Qualls C, Revankar C, Joste N, Prossnitz E.  GPR30: a novel indicator of poor survival for endometrial carcinoma..  American journal of obstetrics and gynecology.  2007 April. 196(4):386.e1-9; discussion 386.e9-11.
[PubMed]

Feldman I, Feldman G, Mobarak C, Dunkelberg J, Leslie K.  Identification of proteins within the nuclear factor-kappa B transcriptional complex including estrogen receptor-alpha..  American journal of obstetrics and gynecology.  2007 April. 196(4):394.e1-11; discussion 394.e11-3.
[PubMed]

Cole L, Dai D, Butler S, Leslie K, Kohorn E.  Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG..  Gynecologic oncology.  2006 August. 102(2):145-50.
[PubMed]

Davies S, Dai D, Pickett G, Leslie K.  Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells..  Gynecologic oncology.  2006 April. 101(1):62-70.
[PubMed]

Smith H, Leslie K, Singh M, Qualls C, Revankar C, Joste J, Prossnitz E.  GPR30: A Novel Indicator of Poor Survival for Endometrial Carcinoma.  American Gynecological and Obstetrical Society, oral presentation by Dr. Smith for membership.  2006. 

Leslie K, Feldman I, Feldman G, Mobarak C, Dunkelberg J.  Identification of Proteins within the Nuclear Factor-kappa B Transcriptional Complex Including Estrogen Receptor-α .  American Gynecological and Obstetrical Society. Oral presentation for membership.  2006. 

Leslie K, Lange C.  Breast cancer and pregnancy..  Obstetrics and gynecology clinics of North America.  2005 December. 32(4):547-58.
[PubMed]

Leslie K.  Cancer Complicating Pregnancy.  Obstetrics and Gynecologic Clinics of North America.  2005 December. 32.

Leslie K, Koil C, Rayburn W.  Chemotherapeutic drugs in pregnancy..  Obstetrics and gynecology clinics of North America.  2005 December. 32(4):627-40.
[PubMed]

Albitar L, Laidler L, Abdallah R, Leslie K.  Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors..  Molecular cancer therapeutics.  2005 December. 4(12):1891-9.
[PubMed]

Dai D, Holmes A, Nguyen T, Davies S, Theele D, Verschraegen C, Leslie K.  A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer..  Cancer research.  2005 October. 65(20):9517-24.
[PubMed]

Leslie K, Dipasquale-Lehnerz P, Smith M.  Obstetric forceps training using visual feedback and the isometric strength testing unit..  Obstetrics and gynecology.  2005 February. 105(2):377-82.
[PubMed]

Leslie K, Marquez-Lago T, Slepoy A, Plimpton S, Oliver J, Steinberg S.  ChemCell mathematical modeling defines a biologically relevant lower limit of progesterone receptors in endometrial cancer.  Society for Gynecologic Investigation.  2005. 

Marquez-Lago T, Slepoy A, Plimpton S, Steinberg S, Oliver J, Leslie K.  ChemCell mathematical modeling to deduce the optimal conditions for progesterone receptor transcriptional activity in endometrial cancer cells.  Keystone Symposium, Monterey, CA.  2005. 

Albitar L, Pickett G, Leslie K.  Differential gene and phosphoprotein regulation by Iressa (ZD1839) in human poorly-differentiated Hec50co endometrial cancer cells.  Keystone Symposium, Monterey, CA.  2005. 

Davies S, Dai D, Pickett G, Leslie K.  Differential gene regulation by the two progesterone receptor isoforms in poorly differentiated Hec50co endometrial cancer cells.  Keystone Symposium, Monterey, CA.  2005. 

Laidler L, Dai D, Leslie K.  Effects of Iressa on endometrial cancer cell lines.  Keystone Symposium, Monterey, CA.  2005. 

Laidler L, Dai D, Leslie K.  Effects of Iressa on endometrial cancer cell lines.  Society for Gynecologic Investigation.  2005. 

Davies S, Dai D, Pickett G, Leslie K.  Genomic analysis identified PRA/PRB as the most transcriptionally active progesterone receptor dimer in human poorly differentiated Hec50co endometrial cancer cells.  Society for Gynecologic Investigation.  2005. 

Dai D, Albitar L, Nguyen T, Laidler L, Singh M, Leslie K.  Inhibition of endometrial cancer growth through re-institution of progesterone signaling.  Keystone Symposium, Monterey, CA.  2005. 

Leslie K, Espey E.  Oral contraceptives and skin cancer: is there a link?.  American journal of clinical dermatology.  2005. 6(6):349-55.
[PubMed]

Davies S, Dai D, Pickett G, Leslie K.  Overlapping but distinct gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa cells.  Society for Gynecologic Investigation.  2005. 

Albitar L, Pickett G, Leslie K.  Phosphoprotein and gene regulation by Iressa (ZD1839) in human poorly-differentiated Hec50co endometrial cancer cells.  Society for Gynecologic Investigation.  2005. 

Bolnick J, Mobarak C, Leslie K.  Proteomic profiling of serum from patients with preterm labor.  Society for Maternal-Fetal Medicine, Reno, NV.  2005. 

Leslie K, Zaino R, Vilaci V, Singh M.  Relationship of estrogen receptor-alpha and progesterone receptors A and B to clinical outcome in metastatic endometrial carcinoma.  Keystone Symposium, Hormonal Regulation of Tumorigenesis, Monterey, CA.  2005. 

Leslie K, Davies S, Singh M, Smith H.  Steroid hormone receptors in normal and malignant endometrium.  Cancer of the Uterus.  2005. 

Dai D, Holmes A, Nguyen T, Davies S, Leslie K.  Synergistic anti-cancer effects of paclitaxel and amifostine in endometrial cancer.  Society for Gynecologic Investigation. Oral presentation.  2005. 

Leslie K, Laidler L, Albitar L, Davies S, Nguyen T, Holmes A, Singh M, Dai D.  Tyrosine Kinase Inhibitors in Endometrial Cancer.  Int J Gynecol Cancers .  2005. 15:409-11.

Dai D, Albitar L, Nguyen T, Laidler L, Singh M, Leslie K.  A therapeutic model for advanced endometrial cancer: systemic progestin in combination with local adenoviral-mediated progesterone receptor expression..  Molecular cancer therapeutics.  2005 January. 4(1):169-75.
[PubMed]

Leslie K, Stein M, Kumar N, Dai D, Stephens J, Wandinger-Ness A, Glueck D.  Progesterone receptor isoform identification and subcellular localization in endometrial cancer..  Gynecologic oncology.  2005 January. 96(1):32-41.
[PubMed]

Davies S, Dai D, Wolf D, Leslie K.  Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells..  Journal of the Society for Gynecologic Investigation.  2004 October. 11(7):494-9.
[PubMed]

Leslie K, Mobarak C, Smith H.  Proteomic screening for endometrial cancer.  The NIH Early Detection Research Network, New York.  2004 September. 

Leslie K.  Tyrosine Kinase Inhibitors in Endometrial Cancer.  M.D. Anderson Second Endometrial Cancer Conference, Houston.  2004 September. 

Davies S, Dai D, Feldman I, Pickett G, Leslie K.  Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2..  Gynecologic oncology.  2004 August. 94(2):463-70.
[PubMed]

Leslie K, Singh M, Zaino R.  GOG 119, Effect of tamoxifen and sequential Provera: relationship of response to hormone receptor status.  Society for Gynecologic Investigation.  2004. 

Leslie K.  Hormones, Genes, and Cancer.  Gynecol Oncol .  2004. 92:389-91.

Davies S, Dai D, Feldman I, Pickett G, Leslie K.  Identification of a novel pathway of inhibition of NF-kappa B by progesterone: induction of A20 and ABIN-2.  Oral presentation: Society for Gynecologic Investigation.  2004. 

Bolnick J, Velazquez M, Leslie K.  Phosphoproteomic analysis of EGFR signaling in first trimester cytotrophoblasts.  Society for Gynecologic Investigation.  2004. 

Bolnick J, Velazquez M, Velazquez M, Albitar L, Laidler L, Leslie K.  Phosphoproteomic Profiling in First Trimester Trophoblasts: EGF/EGFR controls Apoptosis through Akt.  Society for Maternal-Fetal Medicine.  2004. 

Smith H, Singleton S, Qualls C, Kay C, Padilla-Paz L, Leslie K.  Population-Based (SEER 1973-1999) Survival Differences for Papillary Endometrial Carcinoma Subtypes (UPSC) and Adenocarcinomas (ADC).  Society for Gynecologic Oncologists.  2004. 

Dai D, Litman E, Schonteich E, Leslie K.  Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth..  The Journal of steroid biochemistry and molecular biology.  2003 November. 87(3-Feb):123-31.
[PubMed]

Davies S, Dai D, Velazquez M, Laidler L, Wolf D, Leslie K.  Genomic and Non-Genomic Anti-Inflammatory Effects of Progesterone on Endometrial Cancer Cells.  The Society for Gynecologic Investigation.  2003. 

Mobarak C, Davies S, Smith H, Sklar L, Rubin R, Leslie K.  Proteomic Analysis of Serum for the Detection of Endometrial Cancer.  American Association of Cancer Research, Washington, DC.  2003. 

Leslie K.  Chemotherapy and pregnancy..  Clinical obstetrics and gynecology.  2002 March. 45(1):153-64.
[PubMed]

Gibbs R, Davies J, McDuffie R, Leslie K, Sherman M, Centretto C, Wolf D.  Chronic intrauterine infection and inflammation in the preterm rabbit, despite antibiotic therapy..  American journal of obstetrics and gynecology.  2002 February. 186(2):234-9.
[PubMed]

Dai D, Wolf D, Litman E, White M, Leslie K.  Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors..  Cancer research.  2002 February. 62(3):881-6.
[PubMed]

Leslie K.  Adventures in Acquiring a Grant from NIH: One Fellow’s Story.  American Association of Obstetricians and Gynecologists Fellowship Retreat, Kohler,WS.  2002. 

Dai D, Leslie K.  Effects of progesterone on AP-1 transcription factor functions in endometrial cancer cells.  The SAGE (Sex and Gene Expression) III Conference, oral presentation, San Jose, CA.  2002. 

Dai D, Leslie K.  Progesterone regulation of AP-1 transcriptional activity: a mechanism underlying the inhibition of endometrial cancer cell growth.  The Endocrine Society, San Francisco, CA.  2002. 

Leslie K.  Progesterone’s Downstream Effects in Endometrial Cancer: Identification of Potential Biomarkes.  The Gynecologic Oncology Group (GOG), Vancouver, B.C., Canada.  2002. 

Leslie K, Dai D.  The effects of estrogen and progesterone on the female reproductive tract.  The SAGE (Sex and Gene Expression) III Conference, oral presentation, San Jose, CA.  2002. 

Dai D, Kumar N, Wolf D, Leslie K.  Molecular tools to reestablish progestin control of endometrial cancer cell proliferation..  American journal of obstetrics and gynecology.  2001 April. 184(5):790-7.
[PubMed]

McDuffie R, Davies J, Leslie K, Lee S, Sherman M, Gibbs R.  A randomized controlled trial of interleukin-1 receptor antagonist in a rabbit model of ascending infection in pregnancy..  Infectious diseases in obstetrics and gynecology.  2001. 9(4):233-7.
[PubMed]

Wolf D, Dai D, Litman E, White M, Leslie K.  Gene expression analysis of effectors of growth control in endometrial cancer cells after re-introduction of progesterone receptor.  Oral presentation, SGI, Toronto.  2001. 

Dai D, Litman E, Leslie K.  Mechanism of progesterone control of endometrial cancer cell growth: interactions between progesterone receptors and AP-1 factors.  Oral presentation. The Endocrine Society.  2001. 

Dai D, Kumar N, Wolf D, Litman E, Leslie K.  Re-establishing progesterone control of endometrial cancer cell growth.  Oral presentation, SGI, Toronto.  2001. 

Davies J, Shikes R, Sze C, Leslie K, McDuffie R, Romero R, Gibbs R.  Histologic inflammation in the maternal and fetal compartments in a rabbit model of acute intra-amniotic infection..  American journal of obstetrics and gynecology.  2000 November. 183(5):1088-93.
[PubMed]

Kumar N, Litman E, Leslie K.  Differential effects of estrogen and antiestrogens on estrogen and progesterone receptor levels in breast versus endometrial cancer cells.  Endocrine Society, Toronto, Canada.  2000 June. 

Leslie K, Lee S, Woodcock S, Davies J, McDuffie R, Hirsch E, Sherman M, Eskens J, Gibbs R.  Acute intrauterine infection results in an imbalance between pro- and anti-inflammatory cytokines in the pregnant rabbit..  American journal of reproductive immunology (New York, N.Y. : 1989).  2000 May. 43(5):305-11.
[PubMed]

Feldman I, Litman E, Leslie K.  A mechanism for cross-talk between the cytokine and steroid hormone signaling pathways: nuclear factor-Kappa B (NF-kB) binds to the estrogen and progesterone DNA response elements.  Keystone Symposium on Nuclear Receptors 2000, Steamboat Springs, CO.  2000 March. 

Leslie K, Kumar N, Fox K, Stephans J.  A novel mechanism underlying progestin resistance in endometrial cancer: loss of the nuclear localization of progesterone B receptors.  Keystone Symposium on Nuclear Receptors 2000, Steamboat Springs, CO.  2000 March. 

Kumar N, Litman E, Leslie K.  Differential effects of estrogen and antiestrogens on estrogen and progesterone receptor levels in breast versus endometrial cancer cells.  Keystone Symposium on Nuclear Receptors 2000, Steamboat Springs, CO.  2000 March. 

Leslie K, Reznikov L, Simon F, Fennessey P, Reyes H, Ribalta J.  Estrogens in intrahepatic cholestasis of pregnancy..  Obstetrics and gynecology.  2000 March. 95(3):372-6.
[PubMed]

Leslie K.  Breast cancer and Pregnancy.  Medical Care of the Pregnant Woman.  2000. 

Faro S, Fine P, Leslie K.  Gynecological and reproductive health issues.  Report of the Peer Review Panel on the Defense Women’s Health Research Program (DWHRP), .  2000. 

Kumar N, Fox K, Stephens J, Leslie K.  A novel mechanism underlying progestin resistance in endometrial cancer: loss of the nuclear localization of progesterone B receptors.  Endocrine Society, San Diego, CA.  1999 June. 

Kumar N, Litman E, Shmorgun O, Leslie K.  Differential regulation of estrogen receptors by estrogens and anti-estrogens in endometrial versus breast cancer cells.  Endocrine Society, San Diego, CA, June .  1999 June. 

Leslie K, Feldman I.  AA mechanism for cross-talk between the cytokine and steroid hormone signaling pathways in the human placenta: nuclear factor kappa B (NF-kB) binds to the estrogen and progesterone DNA response elements.  Society for Gynecologic Investigation, Atlanta.  1999. 

Leslie K, Lee S, Woodcock S, Davies J, McDuffie R, Hirsch E, Sherman M, Gibbs R.  Acute intrauterine infection associated with preterm delivery results in an imbalance of pro- versus anti-inflammatory cytokines in the rabbit placenta.  Society for Gynecologic Investigation, Atlanta.  1999. 

Leslie K, Kumar N.  Endocrine cancer risks for women during the perimenopause and beyond..  Seminars in reproductive endocrinology.  1999. 17(4):359-70.
[PubMed]

Jerath V, Awoniyi C, Leslie K.  L-arginine and nitric oxide levels in pregnancy: possible correlation with preterm labor and preeclampsia.  Society for Gynecologic Investigation, Atlanta.  1999. 

Davies J, Lee S, Eskens J,  R, Gibbs R, Leslie K.  Nuclear Factor Kappa B, a transcriptional activator of pro-inflammatory cytokines, is expressed and activated in rabbit fetal tissues during infection leading to preterm pregnancy loss.  Society for Maternal-Fetal Medicine, San Francisco.  1999. 

Leslie K, Eskens J, Feldman J, Davies J, McDuffie R, Gibbs R.  Nuclear Factor Kappa B (NF-kB), a transcriptional inducer of pro-inflammatory cytokines, is expressed and activated in the rabbit placenta during infection leading to preterm pregnancy loss.  Infectious Disease Society for Obstetrics and Gynecology, Jackson Hole, WY.  1998 August. 

Kumar N, Richer J, Owen G, Litman E, Horwitz K, Leslie K.  Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action..  Cancer research.  1998 May. 58(9):1860-5.
[PubMed]

Kumar N, Litman E, Richer J, Owen G, Horwitz J, Leslie K.  Down regulation of progesterone receptor B in poorly differentiated endometrial cancer cells.  Keystone Symposium on Steroid and Thyroid Hormones, Lake Tahoe, NV.  1998 April. 

Leslie K, Kumar N, Litman E, Richer J, Owen G, Horwitz K.  Progesterone receptor isoform B is a strong transcriptional activator and a potential marker for well-differentiated endometrial cancer cells.  Society for Gynecologic Investigation, Atlanta, GA.  1998 March. 

Leslie K, Shaffer E.  Transposition of the great vessels ,complete and corrected.  Fetal Echocardiography.  1998. 

Leslie K, Shaffer E.  Univentricular heart.  Fetal Echocardiography.  1998. 

Leslie K, Kumar N, Richer J, Owen G, Takimoto G, Horwitz K, Lange C.  Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation..  Annals of the New York Academy of Sciences.  1997 September. 828:17-26.
[PubMed]

Hurst B, Leslie K.  The role of oestrogen in follicular development..  Molecular human reproduction.  1997 August. 3(8):643-5.
[PubMed]

Kumar N, Richer J, Owen G, Takomoto , Lange C, Horwitz K, Leslie K.  Differential expression of the A and B isoforms of progesterone receptor in endometrial cancer cells: primarily PRB is induced by estrogens and associated with strong transcriptional activation.  Endocrine Society, Minneapolis, MN.  1997 June. 

Leslie K, Reznikov L, McDuffie R, Cominelli F, Melani L, Gibbs R.  Amniotic fluid concentrations of TNF- α versus TGF-2 in a rabbit model of infection-induced preterm birth.  Infectious Diseases Society for Obstetrics and Gynecology, Beaver Creek, CO.  1996 August. 

Leslie K, Reznikov L, Qamar S, Litman E, Pike A, Fennessey P.  The conversion of estrone to estradiol in endometrial and breast cancer cells.  Gordon Research Conference on Reproductive Tract Biology, Plymouth, NH.  1996 July. 

Leslie K, Reznikov L, Qamar S, Litman E, Pike A, Fennessey P.  The conversion of estrone to estradiol in endometrial and breast cancer cells.  Keystone Symposia on Molecular & Cellular Biology, Lake Tahoe, NV.  1996 March. 

Leslie K, Reznikov L.  Intrahepatic cholestasis of pregnancy is associated with abnormal estrogen excretion.  Society of Perinatal Obstetricians, Kona, Hawaii, February 4-10.  1996 February 10. 

Leslie K, Kumar N.  Differential expression and function of the A and B isoforms of progesterone receptors in human endometrial cancer cells in vitro.  Internet World Congress on Biomedical Sciences.  1996. 

Leslie K, Persutte W, Drose J, Lenke R, Hobbins J, Manco-Johnson M, Shaffer E, Wiggins J.  Prenatal detection of heart disease by basic ultrasonography at a tertiary care center: what should our expectations be?.  J Mat Fet Med .  1996. 6:132-135.

Leslie K, Litman E.  The effects of estrogens and antiestrogens on reporter gene transcription on endometrial and breast cancer cells in vitro: models to study the consequences of tamoxifen treatment.  In vitro Biology of Sex Steroid Hormone Action.  1996. 

Pike A, Leslie K, Reznikov L, Fennessey P.  Analysis of Urinary Estrogens by GC/MS from Patients With Cholestasis of Pregnancy.  37th Rocky Mountain Conference on Analytica Chemistry, July 23-27, 1995, Denver, Colorado.  1995 July 27. 

Pike A, Leslie K, Reznikov L, Fennessey P.  Analysis of Urinary Estrogens From Patients With Cholestasis of Pregnancy.  Third International Symposium on Applied Mass Spectrometry in the Health Sciences. European Tandem Mass Spectrometry Conference. Barcelona.  1995 July 13. 

Dugoff L, Leslie K.  Determination of Fetal Rhesus D Status by DNA Amplification.  Society for Gynecologic Investigation.  1995. 

White M, Zamudio S, Stevens T, Tyler R, Lindenfeld J, Leslie K, Moore L.  Estrogen, progesterone and cellular mechanisms of vascular control.  Endocrine Reviews .  1995. 16(6):739-751.

Lederman S, Leslie K, Lidor Y, Lenke R.  Maternal Serum alpha-fetoprotein levels in ectopic pregnancies: A prospective, controlled study.  J Mat Fet Med Invest .  1995. 6:103-112.

Leslie K, Litman E.  The Estrogen Agonist Versus Antagonist Function of Tamoxifen Depends Upon the Cellular Concentration of Estradiol.  Society for Gynecologic Investigation.  1995. 

Hurst B, Zilberstein M, Chou J, Litman B, Stephens J, Leslie K.  Estrogen receptors are present in human granulosa cells..  The Journal of clinical endocrinology and metabolism.  1995 January. 80(1):229-32.
[PubMed]

Kepa J, Neely C, Jacobson B, McDonnell D, Leslie K, Wierman M.  Estrogen receptor mediated regulation of rat gonadotropin releasing hormone (GnRH) promoter activity in hypothalamic cells.  Endocrinology.  1994. 2:947-956.

Leslie K, Keefe D, Powell S, Naftolin F.  Estrogen receptors are identified in the glioblastoma cell line U138MG.  Journal of the Society for Gynecologic Investigation.  1994. 1(3):238-44.
[PubMed]

Leslie K, Litman E.  Estrogenic-Induced Gene Transcription is Enhanced by Cyclic AMP in the Endometrium: Cross Talk Occurs Between the Steroid Hormone and Signal Transduction Pathways.  IX International Congress on Hormonal Steroids.  1994. 

Zamudio S, Leslie K, White M, Hagerman D, Moore L.  Low serum estradiol and high serum progesterone concentrations characterize hypertensive pregnancies at high altitude..  Journal of the Society for Gynecologic Investigation.  1994. 1(3):197-205.
[PubMed]

Leslie K, Litman E.  Tamoxifen Has Complex Estrogenic and Antiestrogenic Activity in the Endometrium and the Breast.  1994. 

Leslie K, Zuckerman D, Schruefer J, Burchell M, Smith J, Albertson B.  Oestrogen modulation with parturition in the human placenta..  Placenta.  1994 January. 15(1):79-88.
[PubMed]

Leslie K, Horowitz K.  Aberrant Responses to Steroid Hormones in Breast and Endometrial Cancer.  Society for Gynecologic Investigation.  1993. 

Leslie K, Moore G, Horwitz K.  Colorado Cell Line 685: A New Model for Hormone-Responsive Endometrial Cancer.  Endocrine Society.  1993. 

Plouzek C, Leslie K, Stephens J, Chou J.  Differential gene expression in the amnion, chorion, and trophoblast of the human placenta..  Placenta.  1993. 14(3):277-85.
[PubMed]

Hurst B, Strand K, Leslie K.  Estrogen Receptor Messenger RNA is Present in Human Granulosa Cells.  American Fertility Society.  1993. 

Silver R, Heyborne K, Leslie K.  Pregnancy specific beta 1 glycoprotein (SP-1) in maternal serum and amniotic fluid; pre-eclampsia, small for gestational age fetus and fetal distress..  Placenta.  1993. 14(5):583-9.
[PubMed]

Leslie K, Persutte W, Lenke R.  Prenatal Detection of Congenital Heart Disease by Routine Ultrasonography at a Level III Center.  American Society of Human Genetics.  1993. 

Leslie K, Keefe D, Powell S, Naftolin F.  The Reverse Transcriptase-Polymerase Chain Reaction Identifies Estrogen Reception mRNA in the Glioblastoma Cell Line HS683.  Society for Gynecologic Investigation.  1993. 

Leslie K, Tasset D, Horwitz K.  Functional analysis of a mutant estrogen receptor isolated from T47Dco breast cancer cells..  American journal of obstetrics and gynecology.  1992 April. 166(4):1053-61.
[PubMed]

Leslie K, Tasset D, Horwitz K.  Functional analysis of a mutant estrogen receptor isolated from T47Dco breast cancer cells..  J Cell Biochem .  1992. 16C:37.

Leslie K, Horwitz K.  Functional Analysis of Mutant Estrogen Receptors and Cellular Heterogeneity in T47Dco Breast Cancer Cells.  Keystone Symposium on Steroid/Thyroid Receptor Gene Super Family, Tammaron, CO.  1992. 

Leslie K, White M, Sujansky E.  Utilization of Polymerase Chain reaction (PCR) for Identification of Estrogen Receptors in Neurofibromas; Potential Clinical Significance.  National Neurofibromatosis Foundation Annual Clinical Care Conference.  1992. 

Leslie K, Horowitz K.  Utilization of Polymerase Chain reaction (PCR) for Identification of Estrogen Receptors in Neurofibromas; Potential Clinical Significance.  National Neurofibromatosis Foundation Annual Clinical Care Conference.  1992. 

Leslie K.  Mutant Estrogen Receptors in Breast and Uterine Cancer.  Burroughs Wellcome, Kennedy-Dannreuther Lecture, American Gynecologic and Obstetrical Society, San Diego.  1991. 

Leslie K.  Physiology of Labor.  In Ob/Gyn Secrets.  1991. 

Horwitz K, Leslie K.  Why are steroid receptor antagonists sometimes agonists? .  Steroid Hormone Receptors.  1991. 

Graham M, Krett N, Miller L, Leslie K, Gordon D, Wood W, Wei L, Horwitz K.  T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance..  Cancer research.  1990 October. 50(19):6208-17.
[PubMed]

Leslie K, Watanabe S, Lei K, Chou D, Plouzek C, Deng H, Torres J, Chou J.  Linkage of two human pregnancy-specific beta 1-glycoprotein genes: one is associated with hydatidiform mole..  Proceedings of the National Academy of Sciences of the United States of America.  1990 August. 87(15):5822-6.
[PubMed]

Chou J, Leslie K, Lei K.  Expression of the Pregnancy-Specific 1-Glycoprotein Gene in Normal and Abnormal Trophoblastic Tissues and Immortalization of Trophoblastic Cells by Adenovirus-SV40 Recombinants.  Second International Conference on the CEA Gene Family, Montreal, Canada.  1990. 

Miller L, Leslie K, Graham M, Francis M, Horowitz K.  Hormone Resistant Breast Cancer is Linked to Genetic Instability and Mutant Estrogen Receptors.  The Endocrine Society.  1990. 

Queenan J, Leslie K.  Preconceptions: Preparation for Pregnancy.  Little, Brown, and Co., New York.  1990. 

Leslie K, Watanabe S, Lei K, Plouzek C, Chou J.  The Isolation, Sequencing, and Characterization of a Human Gene for Pregnancy-Specific Beta 1-Glycoprotein which is Preferentially Expressed in Gestational Trophoblastic Disease.  The Endocrine Society.  1990. 

Krett N, Leslie K, Horowitz K.  Analysis of the Estrogen Receptor Mutation in T47Dco Breast Cancer Cells.  Endocrine Society.  1989. 

Leslie K.  Antenatal Testing.  Information Bulletin for the National Association of Family Practitioners .  1989. 

Leslie K, Falk R.  Changes in Steroid Receptor Concentrations in Labor in the Human Myometrium.  Society for Perinatal Obstetricians.  1988. 

Leslie K, Burchell M, Smith J, Schruefer J, Albertson B.  Placental Aromatase Activity and Estrogen Concentrations in the Term, Preterm, and Postterm Human Placenta.  Society for Gynecologic Investigation.  1988. 

Leslie K, Falk R.  Teaching Primary Care Practitioners about Prenatal Diagnosis Using Maternal Serum Alpha-Fetoprotein Testing as a Model.  Innovations in Medical Education Exhibit, Association of American Colleges Annual Meeting, Washington, D.C.  1987 November. 

Leslie K, King J.  Blood Pressure Changes in the Upper and Lower Extremities Following Epidural Anesthesia .  Society for Obstetrical and Anesthesia and Perinatology, Salt Lake City, Utah.  1986 May. 

Brachova P, Mueting S, Devor E, Leslie K.  Oncomorphic TP53 Mutations in Gynecologic Cancers Lose the Normal Protein: Protein Interactions with the MicroRNA Microprocessing Complex.  J Cancer Ther. (Accepted 2014). 

Date Last Modified: 06/07/2014 - 21:56:23